Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases-Reference-Cited by-同舟云学术

Recent Developments in Inhibitors of Bacterial Type IIA Topoisomerases

Published:2013-10-04 Issue: Volume: Page:263-297
ISSN:
Container-title:Antibiotics
language:
Short-container-title:

Author:

Chan Pan F.,Huang Jianzhong,Bax Benjamin D.,Gwynn Michael N.

Publisher

Wiley-VCH Verlag GmbH & Co. KGaA

Reference137 articles.

1. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America;Talbot;Clin. Infect. Dis.,2006

2. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;Boucher;Clin. Infect. Dis.,2009

3. Infectious Diseases Society of America 2010 Call for Action for a Global Commitment to Develop 10 Novel Antibacterial Drugs by 2020 (10 X '20) http://www.idsociety.org

4. Challenges of antibacterial discovery;Silver;Clin. Microbiol. Rev.,2011

5. Drugs for bad bugs: confronting the challenges of antibacterial discovery;Payne;Nat. Rev. Drug Discovery,2007

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nybomycin Inhibits both Fluoroquinolone-Sensitive and Fluoroquinolone-Resistant Escherichia coli DNA Gyrase;Antimicrobial Agents and Chemotherapy;2021-04-19

2. A new class of antibacterials, the imidazopyrazinones, reveal structural transitions involved in DNA gyrase poisoning and mechanisms of resistance;Nucleic Acids Research;2018-03-10

3. Topoisomerases as anticancer targets;Biochemical Journal;2018-01-23

4. Molecular docking studies on thirteen fluoroquinolines with human topoisomerase II a and b;In Silico Pharmacology;2017-06-30

5. Crystallization and initial crystallographic analysis of covalent DNA-cleavage complexes of Staphyloccocus aureus DNA gyrase with QPT-1, moxifloxacin and etoposide;Acta Crystallographica Section F Structural Biology Communications;2015-09-23